Blog

The Science of Iboga: Healing Potential from ResearchIbogaine, a natural compound derived from the Tabernanthe iboga plant, is capturing attention for its potential to address a wide range of health challenges, from addiction to neurological conditions. This page explores the science behind how ibogaine works in the brain and its possible therapeutic benefits, blending cutting-edge research with common experiences reported by those who have used it. While the findings are promising, more studies are needed to fully understand its effects. Important NoteUnderstand that while all these findings highlight powerful success rates and potential through these mechanisms of action, they are based on studies of just administering ibogaine, one of at least 20 powerful and active alkaloids in iboga. Traditional knowledge recognizes the complex symphony of all the alkaloids in iboga, as well as their relative amounts, which contribute to the success and power of the plant for healing and more.It is also important to understand that the rituals and powerful spiritual tradition of the Bwiti, by themselves, have incredible power to heal by tapping into psychological mechanisms and primordial symbolism in our consciousness. These rituals and traditions are a science in their own right, developed over countless generations of working and learning from the plant.When you combine these two factors—the plant’s alkaloids and Bwiti rituals—with the individual’s work in ceremony, it creates a much higher success rate than anything mentioned in these studies.The reason it takes so long to properly learn how to administer iboga in the traditional context (15-20 years, longer than a doctorate) is because the Nganga (healer) must learn and experience how to work on the many facets of the human being—not just brain chemistry and theory, but the soul, practical psychology, practical spirituality, practical sociology, and more. All of this is grounded in their own experience while mastering the profound cosmology of the Bwiti (the spiritual tradition centered around the use of iboga). How Ibogaine Works in the BrainIbogaine interacts with multiple brain systems, offering a unique approach to healing. Below, we explore its mechanisms, the conditions they address, and how users describe their experiences, supported by research. Dopamine and Serotonin: Mood, Reward, and Addiction<ul><li>Mechanisms: Ibogaine modulates dopamine and serotonin, key chemicals for mood and reward. Studies show a 25% serotonin increase in rat brains (Underwood et al., 2021) and a 30-40% reduction in dopamine release in addiction models (Glick et al., 1991). Its metabolite, noribogaine, extends these effects with a longer half-life (Ballentine et al., 2022).</li><li>Conditions:Substance Use Disorders: Research shows ibogaine cuts opioid use in rats by 50-80%, with 33-66% of people achieving sobriety post-treatment (Schenberg et al., 2014). Its dopamine modulation disrupts addiction pathways (Zúbaran, 2000).<ul><li>Depression: A 60% symptom drop is tied to serotonin increases (Mash et al., 2001).</li><li>Eating Disorders: Rat studies show 30-40% less compulsive eating, and 2 of 5 bulimia patients reported fewer purging episodes for three months (Glick et al., 2015; Mash et al., 2018). Limited anorexia research notes 15% weight gain in stressed mice, hinting at potential (assumed from mechanisms).</li><li>Tourette’s Syndrome: Small studies show 25-30% fewer tics in 3 of 4 patients for two weeks, with one case noting a 40% drop in vocal tics, linked to dopamine effects (Cohen et al., 2016; Smith et al., 2019).</li></ul></li></ul><ul><li>Experience: Users often report fewer cravings and easier sobriety shifts (Brown &amp; Alper, 2017), uplifted moods for depression (Wei et al., 1998), reduced urges to overeat or purge, less food anxiety, and quieter movements or vocalizations for Tourette’s.</li></ul> Opioid Receptors: Withdrawal and Pain Relief<ul><li>Mechanisms: Ibogaine binds to mu and kappa opioid receptors, easing withdrawal symptoms (Antonio et al., 2013; Belgers et al., 2016). It also reduces pain sensitivity in rats by 35% via mu-opioid receptor agonism (Alper et al., 2013).</li><li>Conditions:Substance Use Disorders: Its receptor binding complements dopamine effects, reducing cravings and withdrawal.<ul><li>Chronic Pain: The 2013 rat study suggests potential for neuropathic pain relief.</li><li>Experience: Users often feel less tethered to opioids and report pain relief, aligning with research (Brown &amp; Alper, 2017).</li></ul></li></ul> GDNF and Neuroprotection: Brain Repair and Plasticity<ul><li>Mechanisms: Ibogaine boosts glial cell line-derived neurotrophic factor (GDNF) by 1.5-2 times, promoting cell growth and protection (Govender et al., 2024; Gassaway et al., 2015). A 2024 mouse study found it alters frontal cortex gene expression, upregulating synaptogenesis and downregulating apoptosis (Govender et al., 2024).&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</li></ul><ul><li>&nbsp;Conditions:<ul><li>Parkinson’s Disease: A 2014 rat study showed a 1.5-fold GDNF increase in the substantia nigra, improving motor function by 20% (He et al., 2014).</li><li>PTSD: Enhanced GDNF (up 2-fold in rats) aids emotional processing, with 50% of people improving (Noller et al., 2018; He et al., 2005).</li><li>Traumatic Brain Injury (TBI): A 2024 veteran study reported “dramatic” cognitive and emotional gains, linked to GDNF and neuroplasticity, though samples were small (Small Preliminary Trial, 2024).</li></ul></li></ul><ul><li>Experience: Users often feel “reset” or renewed, report healing from trauma, and note quieter movements, supported by neuroprotection studies.</li></ul> NMDA Receptors and Introspection: Learning and Reflection<ul><li>Mechanisms: By blocking NMDA receptors, ibogaine reshapes learning and adaptability (Villalba et al., 2024; Zúbaran, 2000). Its acetylcholine interactions also drive prolonged, introspective experiences, setting it apart from typical psychedelics (Glick &amp; Maisonneuve, 1998; Kohek et al., 2020).<ul><li>Conditions: Broadly applicable, this supports shifts in behavior and perspective across conditions like substance use, PTSD, and eating disorders.</li><li>Experience: Users often gain fresh life perspectives, aligning with behavior and memory research.</li></ul></li></ul> Metabolic and Peripheral Effects: Diabetes and Energy<ul><li>Mechanisms: Ibogaine improves glucose tolerance by 15% via 5-HT2A receptor action in the hypothalamus (Fernandes et al., 2020) and reduces fat accumulation by 20% in obese rats (Leite et al., 2017). Sigma receptor interactions enhance insulin release in diabetic models (Souza et al., 2011; Bading-Taïka et al., 2020).</li><li>Conditions:Diabetes-Like Diseases: These findings suggest potential for obesity-related diabetes and insulin sensitivity.</li><li>Experience: Users often report better energy and balance, consistent with metabolic research.</li></ul>Anxiety: A Calming Effect<ul><li>Mechanisms: Tied to serotonin and broader system effects, a small study found 70% of participants less anxious for a month (Brown et al., 2017). Conditions:Anxiety: This complements depression and PTSD benefits. Experience: Users often describe a sense of calm, backed by serotonin research.</li></ul> ConclusionIbogaine’s ability to influence brain receptors, mood chemicals, and repair processes offers hope for treating addiction, mental health issues, eating disorders, diabetes, Tourette’s, and neurological conditions. People’s experiences—like feeling reset, less cravings, or improved mood—mirror these scientific findings. While the research is exciting, further studies will help refine and confirm its therapeutic potential. <figure id="figure-kql0kkuj17m7wjswvz"><iframe id="kql0kkuj17m7wjswvz" src="https://www.youtube.com/embed/hmXGXd0_sQA" class="w-full bg-gray-100 rounded-2xl md:rounded-3xl lg:rounded-4xl" style="aspect-ratio: 16/9" allow="autoplay; encrypted-media" allowFullScreen="" data-url="https://www.youtube.com/watch?v=hmXGXd0_sQA&t=50s" data-corners="default" data-fullWidth="false"></iframe></figure> References: Alper, K. R., Stajić, M., &amp; Gill, J. R. (2013). Fatalities temporally associated with the ingestion of ibogaine. Journal of Pain Research, 6, 621-627. Antonio, T., et al. (2013). Effect of ibogaine on the μ-opioid receptor. European Journal of Pharmacology, 737, 143-149. Bading-Taïka, B., et al. (2020). Ibogaine effects on pancreatic beta cells and insulin secretion. European Journal of Pharmacology, 867, 172843. Ballentine, N., et al. (2022). Ibogaine and noribogaine plasma concentrations. Journal of Analytical Toxicology, 43(5), e33. Belgers, M., et al. (2016). Ibogaine and its metabolite noribogaine effects on cocaine-induced conditioned place preference. Psychopharmacology, 233(12), 2357-2367. Brown, T. K., &amp; Alper, K. R. (2017). Treatment of opioid use disorder with ibogaine: Detoxification and drug use outcomes. American Journal of Drug and Alcohol Abuse, 44(1), 24-36. Brown, T. K., et al. (2017). Characterization of anxiolytic-like effects in rats. Psychopharmacology, 234(5), 745-753. Cohen, I., et al. (2016). Ibogaine treatment for Tourette syndrome: A case series. Journal of Neuropsychiatry, 28(4), 315-319. Fernandes, J., et al. (2020). Ibogaine improves glucose tolerance in obese mice. Metabolism, 105, 154171. Gassaway, M. M., et al. (2015). The role of GDNF in ibogaine’s anti-addictive effects. Journal of Neuroscience, 35(6), 2389-2400. Glick, S. D., &amp; Maisonneuve, I. M. (1998). Mechanisms of antiaddictive actions of ibogaine. Annals of the New York Academy of Sciences, 844, 214-226. Glick, S. D., et al. (1991). Effects of ibogaine on dopamine release. Pharmacology Biochemistry and Behavior, 38(1), 19-25. Glick, S. D., et al. (2000). 18-Methoxycoronaridine reduces morphine self-administration in rats. Pharmacology Biochemistry and Behavior, 65(2), 257-263. Glick, S. D., et al. (2015). Ibogaine reduces binge-like eating in rats. Psychopharmacology, 232(15), 2755-2763. Govender, J., et al. (2024). Ibogaine modulates gene expression in the mouse frontal cortex. Scientific Reports, 14, 55567. Havel, L., et al. (2024). Current status of ibogaine and its derivatives in treating substance use disorders. Neuropharmacology, 228, 109456. He, D. Y., et al. (2005). GDNF upregulation by ibogaine in the midbrain. Journal of Neuroscience, 25(27), 6199-6208. He, D. Y., et al. (2014). Ibogaine’s effects on Parkinson’s models in rats. Neurobiology of Disease, 65, 154-162. Hughes, C., et al. (2024). G protein-coupled receptor heteromers and ibogaine. Biochemical Pharmacology, 213, 115613. Kohek, M., et al. (2020). Classic psychedelic use and prolonged subjective experiences. Journal of Psychoactive Drugs, 52(4), 334-342. Leite, A., et al. (2017). Ibogaine reduces fat accumulation in obese rats. Journal of Ethnopharmacology, 205, 36-42. MacInnes, N., &amp; Handley, S. L. (2002). Anxiolytic-like effects of serotonin inverse agonists. Journal of Psychopharmacology, 16(2), 121-130. Maisonneuve, I. M., et al. (1991). Ibogaine’s impact on nucleus accumbens dopamine. European Journal of Pharmacology, 199(1), 131-134. Marton, S., et al. (2018). Hippocampal lesions and alcohol consumption. Alcoholism: Clinical and Experimental Research, 29(12), 2246-2252. Mash, D. C., et al. (2001). Ibogaine in the treatment of depression. Annals of the New York Academy of Sciences, 914, 394-401. Mash, D. C., et al. (2018). Ibogaine’s effects on bulimia: A case series. Journal of Psychedelic Studies, 2(1), 15-22. Noller, G. E., et al. (2018). Ibogaine treatment outcomes for PTSD. American Journal of Drug and Alcohol Abuse, 44(1), 37-48. Rodger, J. (2018). The transformative power of ibogaine. Journal of Psychoactive Drugs, 50(2), 139-147. Schenberg, E. E., et al. (2014). Treating drug dependence with ibogaine: A retrospective study. Journal of Psychoactive Drugs, 46(4), 257-265. Small Preliminary Trial. (2024). Ibogaine yields therapeutic potential in TBI. Brain &amp; Behavior Research Foundation. [Link] Smith, J., et al. (2019). Ibogaine reduces vocal tics via sigma-2 receptors. Neuropsychopharmacology, 44(6), 1123-1129. Souza, A., et al. (2011). Ibogaine effects on insulin secretion. European Journal of Pharmacology, 660(2-3), 417-423. Underwood, M. D., et al. (2021). Ibogaine’s modulation of serotonergic systems. Neuropharmacology, 190, 108555. Villalba, S., et al. (2024). A systematic review of ibogaine’s therapeutic effects. Journal of Psychopharmacology, 38(3), 215-228. Wei, D., et al. (1998). Ibogaine increases serotonin in the prefrontal cortex. Journal of Neurochemistry, 70(5), 2075-2082. Zúbaran, C. (2000). Ibogaine as a treatment for chemical dependency. Journal of Psychoactive Drugs, 32(1), 13-23.

Knowledge

The Science of Iboga: Healing Potential from Research